Chronic pain remains a major problem worldwide, despite the availability of various non-pharmacological and pharmacological treatment options. Therefore, new analgesics with novel mechanisms of action are needed. Monoclonal antibodies (mAbs) are directed against specific, targeted molecules involved in pain signaling and processing pathways that look to be very effective and promising as a novel therapy in pain management. Thus, there are mAbs against tumor necrosis factor (TNF), nerve growth factor (NGF), calcitonin gene-related peptide (CGRP), or interleukin-6 (IL-6), among others, which are already recommended in the treatment of chronic pain conditions such as osteoarthritis, chronic lower back pain, migraine, or rheumatoid arthritis that are under preclinical research. This narrative review summarizes the preclinical and clinical evidence supporting the use of these agents in the treatment of chronic pain.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8508878 | PMC |
| http://dx.doi.org/10.3390/ijms221910325 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Gendered dimension of chronic pain patients with low and middle income: A text mining analysis.
PLoS One
December 2024
Iscte-University Institute of Lisbon, Centre for Social Research and Intervention (Cis-Iscte), Lisbon, Portugal.
Methods: This is a mixed-method study using individual interviews (duration between 40-60 minutes) of 181 CNCP patients (71% females) in a tertiary Pain Care Unit, and applying the text mining methodology. Incomes (low or middle) and gender roles (productive vs. reproductive)".
View Article and Find Full Text PDFImpact of SCN10A Polymorphism on Abdominal Pain Perception and Visceral Hypoalgesia in Crohn's Disease and Ulcerative Colitis.
Clin Transl Gastroenterol
December 2024
Department of Pharmacology, Penn State College of Medicine, Hershey, Pennsylvania, USA.
Introduction: Hypoalgesic inflammatory bowel disease (IBD) may provide critical insights into human abdominal pain. This condition was previously associated with homozygosity for a polymorphism (rs6795970, A1073V; 1073 val/val ) related to Na v 1.8, a voltage-gated sodium channel preferentially expressed on nociceptors.
View Article and Find Full Text PDFDorsal Root Ganglion Stimulation for Chronic Pelvic Pain Secondary to Endometriosis.
Neuromodulation
December 2024
Functional and Pain Clinic, Sao Paulo, SP, Brazil; Pediatric Neurosurgery, Washington University in St. Louis, St Louis, MO, USA. Electronic address:
Introduction: Chronic pelvic pain (CPP) is a multifaceted condition that poses significant challenges in clinical management owing to its complex and varied pathophysiology, including neuropathic, somatic, visceral, and musculoskeletal components. Endometriosis is frequently associated with CPP, necessitating a comprehensive, multimodal treatment strategy. This approach typically includes physical and behavioral therapy, pharmacologic interventions, surgical management of endometriosis, and various pain-modulating procedures.
View Article and Find Full Text PDFEvolving Landscape of Sickle Cell Anemia Management in Africa: A Critical Review.
Trop Med Infect Dis
November 2024
School of Health Systems & Public Health, University of Pretoria, Pretoria 0028, South Africa.
Sickle cell disease (SCD) is a prevalent inherited blood disorder, particularly affecting populations in Africa. This review examined the disease's burden, its diverse clinical presentations, and the challenges associated with its management in African settings. Africa bears a significant burden of SCD, with prevalence varying across countries and age groups.
View Article and Find Full Text PDFThe Lack of Effect of Botulinum Toxin-A on Upper Limb Activity in Chronic Stroke: A Short Report from the InTENSE Trial.
Toxins (Basel)
November 2024
Alfred Health, Melbourne, VIC 3004, Australia.
We examined the effect of botulinum toxin-A on upper limb impairments and activity limitations in chronic stroke. This study is a secondary analysis of control group data from a national, multicenter, Phase III randomized trial with a masked outcome assessment. We studied 71 stroke survivors who received a botulinum toxin-A injection in any muscle(s) that crosses the wrist due to significant spasticity after a stroke greater than 3 months previously.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!